Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes

Br J Haematol. 2002 Mar;116(3):601-3. doi: 10.1046/j.0007-1048.2001.03329.x.


We previously reported the establishment of a Wilms' tumour (WT)1-derived peptide (CMTWNQMNL)-specific and human leucocyte antigen (HLA)-A24-restricted anti-leukaemia cytotoxic T lymphocyte (CTL) line, TAK-1. In this study, we have established a novel WT1-derived peptide (RWPSCQKKF)-specific CD8+ CTL line, designated NIM-1. NIM-1 lysed HLA-A24-positive leukaemia cells, but not HLA-A24-negative leukaemia cells or normal cells. The effects of TAK-1 and NIM-1 on cytotoxicity against leukaemia cells were not synergistic, suggesting that recognition of a single epitope on the tumour-specific antigen by CTLs is sufficient to exert maximal cytotoxic activity against tumour cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes / immunology*
  • Cell Line
  • Cytotoxicity, Immunologic
  • HLA-A Antigens / immunology*
  • HLA-A24 Antigen
  • Humans
  • Leukemia / immunology*
  • Tumor Cells, Cultured
  • WT1 Proteins / immunology*


  • HLA-A Antigens
  • HLA-A24 Antigen
  • WT1 Proteins